House dust mite subcutaneous immunotherapy in Chinese patients with allergic asthma and rhinitis

Feng, Mulin; Zeng, Xiaohui; Li, Jing

doi:10.21037/jtd.2019.06.35

Cited by 10 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Randomize, prospektif, tek ve çift kör plasebo kontrollü çalışmalar alerjik rinitte konvansiyonel immünoterapinin etkinliğini göstermiştir (15). İmmünoterapi alerjen ekstresinin düşük dozdan başlanarak artan dozlarda, belirli aralıklarla hastaya verilmesi ve alerjenin tolere edilmesinin sağlanması esasına dayanmaktadır (16,17). Dolayısıyla AİT gündeme geldiği zaman kişinin AR, astım ve konjunktivitinin aslında tek bir hastalığın farklı parçaları olarak kabul edilmesi uygun olacaktır (18).…”

Section: Discussionunclassified

Alerjen Spesifik İmmünoterapi: Etkinliği ve Yaşam Kalitesi Üzerine Etkileri

Erdoğan

Peker

Sin

2021

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi

View full text Add to dashboard Cite

Objective: Allergen specific immunotherapy (AIT) is a treatment modality used in patients with seasonal or perennial allergic rhinitis (AR) and allergen-triggered asthma. In this study, the effects of subcutaneous AIT application with conventional method with standardized allergen extracts on clinical symptoms, drug use and quality of life were evaluated. Material and Methods:In our survey study, 145 patients who received AIT were grouped according to the duration of treatment and the allergen content in the extracts. As the clinical efficacy evaluation parameters, pre-and post-AIT asthma, rhinitis, conjunctivitis symptom score and drug use score were used. Validated "Rhinoconjunctivitis Quality of Life Scale" (RQLQ) and "Asthma Quality of Life Scale" (AQLQ) were applied in order to evaluate the effectiveness of AIT according to the perspective of patients. The general evaluation of allergic disease before and after AIT was made by the patient subjectively as % improvement and by the physician using visual analog scale (VAS).Results: A total of 145 patients (56 women and 89 men) with a mean age of 36.5±10.3 years were enrolled in the study. Among the study group %70.3 of patients had rhinitis and %28.3 of them had both rhinitis and asthma. The decreases in the symptom scores, medication scores and VAS scores were found statistically significant in most of the groups (p< 0,05). Quality of life assessment showed a significant improvement in all patients after AIT compared to pretreatment values. Conclusions:Allergen spesific immunotherapy is a safe and efficient treatment modality in allergic rhinitis and asthma if used properly and with a correct indication. Quality of life measures is an important way to assess the secondary outcomes of AIT.

show abstract

Section: Discussionunclassified

Alerjen Spesifik İmmünoterapi: Etkinliği ve Yaşam Kalitesi Üzerine Etkileri

Erdoğan

Peker

Sin

2021

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi

View full text Add to dashboard Cite

show abstract

“…In addition, with economic development, acceleration of industrialization, and lifestyle changes in China, the morbidity rate of AR has increased. It has been reported that approximately 30 million patients are diagnosed with AR in China every year [ 3 , 4 ]. Therefore, AR has triggered significant public health problems worldwide.…”

Section: Introductionmentioning

confidence: 99%

Febuxostat Alleviates Allergic Rhinitis by Inhibiting Inflammation and Monocyte Adhesion in Human Nasal Epithelial Cells via Regulating KLF6

Yao

Wei

Jiang

2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Introduction. Febuxostat is a novel inhibitor of xanthine oxidase that suppresses cell adhesion molecules-mediated (CAMs) inflammation by activating KLF6. In this study, we explored the therapeutic function and potential mechanisms of febuxostat against allergic rhinitis (AR). Methods. We investigated the role of febuxostat through in vitro cell and in vivo animal experiments. Human nasal epithelial cells (hNECs) were cultured with histamine as an in vitro model. To establish the AR animal model, rats were exposed to ovalbumin. Rats were randomly grouped into control, model, 7.5 mg/kg febuxostat, and 15 mg/kg febuxostat groups. Results. In the in vitro study, we found significantly increased release of lactate dehydrogenase, elevated production of inflammatory factors and chemokines, and upregulated CAMs in histamine-treated hNECs. However, these results were significantly reversed for the 10 and 20 μM febuxostat treatments. The enhanced adhesion between hNECs and monocytes induced by histamine was dramatically repressed by febuxostat. In the vivo experiments, we observed that febuxostat ameliorated the increased sneezing times, the number of nose scratching episodes, and elevated HE pathological scores as well as alleviated the inflammation in nasal mucous tissues of AR mice. We found that KLF6, which was downregulated in histamine-treated hNECs, was significantly upregulated by febuxostat. The inhibitory effects of febuxostat on the expression levels of CAMs and adhesion between histamine-treated hNECs and monocytes were significantly abolished by the knockdown of KLF6. Conclusion. Febuxostat alleviates AR by inhibiting inflammation and monocyte adhesion in human nasal epithelial cells through the regulation of KLF6.

show abstract

A novel dose-adjustment protocol for interrupted subcutaneous immunotherapy in children with allergic rhinitis

Pan,

Xue

2024

Immunotherapy

View full text Add to dashboard Cite

Aim: To assess the effectiveness and safety of a new protocol for adjusting doses during interrupted subcutaneous immunotherapy maintenance, exceeding an 8-week interval, with mite allergen injections in children with allergic rhinitis. Patients & methods: 194 children with allergic rhinitis who underwent subcutaneous immunotherapy and experienced interruptions lasting more than 8 weeks during maintenance were enrolled. Following the adoption of a novel dose-adjustment protocol, a real-world study was conducted. Results: After 3 years of subcutaneous immunotherapy, the novel group exhibited a significant reduction in allergy symptoms compared with baseline. Systemic reactions related to the novel protocol did not significantly increase. Conclusion: The novel protocol was deemed safe and effective, offering advantages of time savings and reduced burdens.

show abstract

House dust mite subcutaneous immunotherapy in Chinese patients with allergic asthma and rhinitis

Cited by 10 publications

References 23 publications

Alerjen Spesifik İmmünoterapi: Etkinliği ve Yaşam Kalitesi Üzerine Etkileri

Alerjen Spesifik İmmünoterapi: Etkinliği ve Yaşam Kalitesi Üzerine Etkileri

Febuxostat Alleviates Allergic Rhinitis by Inhibiting Inflammation and Monocyte Adhesion in Human Nasal Epithelial Cells via Regulating KLF6

A novel dose-adjustment protocol for interrupted subcutaneous immunotherapy in children with allergic rhinitis

Contact Info

Product

Resources

About